Form 8-K AVEO PHARMACEUTICALS For: Jan 19

�

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

�

�

FORM 8-K

�

�

CURRENT REPORT

Pursuant to Section�13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January�19, 2015

�

�

AVEO Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

�

�

�

Delaware	�	001-34655	�	04-3581650
(State or Other Jurisdiction of Incorporation)	�	(Commission File Number)	�	(IRS Employer Identification No.)

�

650 East Kendall Street Cambridge, Massachusetts	�	02142
(Address of Principal Executive Offices)	�	(Zip Code)

Registrant�s telephone number, including area code: (617)�299-5000

�

(Former Name or Former Address, if Changed Since Last Report)

�

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

�

�	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

�

�	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

�	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

�

�	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

�

---

Item�5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On January�19, 2015, Matthew Dallas, Vice President, Finance, Treasurer and the principal accounting officer of AVEO Pharmaceuticals, Inc. (the �Company�), announced that he will be leaving the Company on February�6, 2015 to pursue a new career opportunity.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

AVEO Pharmaceuticals, Inc.
Date: January 22, 2015
By:	�	/s/ Michael Bailey
	�	Michael Bailey
	�	President and Chief Executive Officer

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Genie Energy to Report First Quarter 2024 Results
• MiMedia Enters Into Market-Making Agreement with Independent Trading Group
• Methanex Corporation – Notice of Cash Dividend